Jun 17 |
Immix Biopharma to Present at the Stifel 2024 Cell Therapy Forum
|
Jun 10 |
RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships
|
May 23 |
Immix Biopharma Insiders Placed Bullish Bets Worth US$625.7k
|
May 10 |
Immix Biopharma Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Late Breaking Oral Presentation
|
Apr 29 |
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma
|
Apr 18 |
Immix Biopharma on Track to Dose NXC-201 Patients in United States
|
Apr 15 |
Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
|
Mar 20 |
Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial
|
Mar 5 |
Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative
|
Feb 21 |
Immix Biopharma 12 Month Review Progress Update
|